RCS - Ondine Biomedical - Steriwave shown to reduce resistant bacteria

Ondine BiomedicalAnnouncement

18/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231018:nRSR4499Qa&default-theme=true

RNS Number : 4499Q  Ondine Biomedical Inc.  18 October 2023

18 October 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave shown to reduce resistant bacteria by >99.9%

·    New research presented by Ondine shows that Steriwave
photodisinfection reduces antibiotic-resistant bacteria by more than 99.9%
without generating resistance.

·    The research suggests that photodisinfection is a viable alternative
to antibiotics.

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today
presenting new research showing that Steriwave® photodisinfection reduced
antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is
being presented today at the IP2023 Annual conference taking place in
Liverpool 17-19 October 2023, indicates that photodisinfection is likely to
play an important role in strategies for combatting antimicrobial resistance
(AMR).

The controlled study evaluated the efficacy of Ondine's Steriwave®
photodisinfection against Gram-negative and Gram-positive multidrug-resistant
(MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic
resistance factors. All of the bacterial strains used in the study exhibited
resistance against some of the most commonly prescribed antibiotic classes,
including penicillin, tetracyclines, quinolones and carbapenems.

The results of the study showed that treatment with photodisinfection resulted
in >99.9% reduction of viable bacteria compared to the control, regardless
of the antibiotic susceptibility of the bacteria. The authors concluded that
photodisinfection is likely an important adjunct to AMR strategies in the
future and that further clinical studies are warranted.

Antimicrobial resistance (AMR) remains a major public health concern, causing
33,000 deaths in Europe annually( 1  (#_edn1) ) which is projected to rise to
over 10 million globally by 2050.( 2  (#_edn2) ) There are widespread
multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections
across the world which are mainly caused by Gram-negative bacteria including
Enterobacteriaceae and P. aeruginosa AMR bacteria( 3  (#_edn3) )(,( 4 
(#_edn4) )) and Gram-positive bacteria such as Staphylococcus spp.( 5 
(#_edn5) ) Steriwave has been found to be highly effective against all these
pathogens.

Photodisinfection uses a photosensitizer and a specific wavelength of light to
trigger photochemical reactions that produce reactive oxygen species. These
reactive oxygen species are lethal to a broad spectrum of microbes, including
bacteria, fungi, and viruses. Importantly, photodisinfection does not induce
antimicrobial resistance formation.

Carolyn Cross, CEO of Ondine, commented:

"We continue to demonstrate, both clinically in hospitals across Canada and in
the lab, that photodisinfection can provide a real alternative to topical
antimicrobials which are no longer effective against an increasing number of
pathogens. The evidence continues to show that photodisinfection destroys all
types of pathogens including viruses, bacteria and fungi even those in
biofilm, and we believe this technology can save millions of lives. The
results of this study are particularly welcome as we prepare for our US Phase
3 trial in partnership with HCA Healthcare who are providing invaluable
guidance and support."

The poster presentation, "Antimicrobial Photodynamic Therapy Against
Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic
Resistance Factors", is being presented at IP2023 between 1:10pm and 2:40pm
(BST) on 18 October 2023. The full poster is available to download here
(https://ondinebio.com/wp-content/uploads/2023/10/IPS-Poster-Photodisinfection-against-MDR-and-XDR-bacteria.pdf)
.

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

About photodisinfection

Ondine's photodisinfection is a patented technology using a proprietary
photosensitizer (non-antibiotic, light-activated solution) to destroy
pathogens. When illuminated with a specific wavelength of light, the
photosensitizer is activated, causing an oxidative burst that is lethal to all
types of pathogens.

Ondine's nasal photodisinfection system has a CE mark and is approved in
Canada and several other countries under the name Steriwave™. It has been
used in Canada for over ten years, with no serious adverse events reported. In
the US, it is currently undergoing clinical trials for regulatory approval.

 1  (#_ednref1) WHO Regional Office for Europe/European Centre for Disease
Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 -
2020 data. Copenhagen: WHO Regional Office for Europe; 2022.

 2  (#_ednref2) "O'Neill Review into Antibiotic Resistance"
https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf
(https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf)

 3  (#_ednref3) Cassini A, Högberg LD, Plachouras D, et al. Attributable
deaths and disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European Economic Area in
2015: a population-level modelling analysis. Lancet Infect Dis.
2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4

 4  (#_ednref4) Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant
Gram-negative bacteria: a systematic review of current epidemiology, prognosis
and treatment options. J Antimicrob Chemother. 2020;75(2):271-282.
doi:10.1093/jac/dkz401

 5  (#_ednref5) UK Health Security Agency. MRSA, MSSA, Gram-negative
bacteraemia and CDI: 30-day all-cause fatality, London: UK Health Security
Agency, March 2023.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBSAROBURAUA